Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma.
Brain metastasis
HPV
Head and neck cancer
Head and neck squamous cell carcinoma
Human papillomavirus
MAP2K2
Molecular
Next-generation sequencing
PD-L1
TSC1
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
22 Oct 2024
22 Oct 2024
Historique:
received:
12
09
2024
accepted:
10
10
2024
medline:
23
10
2024
pubmed:
23
10
2024
entrez:
22
10
2024
Statut:
epublish
Résumé
Brain metastasis (BM) is a rare but severe complication of head and neck squamous cell carcinoma (HNSCC), with limited knowledge of molecular characteristics and immunogenicity. We analyzed 61 cases of HNSCC-BM from three academic institutions (n = 24) and Foundation Medicine Inc (FMI, n = 37). A subset of cases underwent next-generation sequencing, multiple immunofluorescence, and proximity ligation sequencing. Gene enrichment analysis compared alterations in FMI BM samples (n = 37) with local samples (n = 4082). Demographics included: median age of 59 years, 75% male, 55% current/former smokers, 75% oropharyngeal primary, and 67% human papillomavirus (HPV) +. ATM (54%), KMT2A (54%), PTEN (46%), RB1 (46%), and TP53 (46%) were frequently altered in BM samples from academic centers (62% HPV/p16+). Structural rearrangements ranged from 9 to 90 variants by proximity ligation sequencing. BMs had low densities of CD8+, PD-1+, PD-L1+, and FOXP3 + cells, and 92% had PD-L1 combined positive scores < 1%. CDKN2A (40.5%), TP53 (37.8%), and PIK3CA (27.0%) alterations were common in the FMI BMs (51% HPV+). MAP2K2 alterations and HPV + signature were enriched in FMI BMs compared to local tumors (11.8% vs. 6.4%, P = 0.005 and 51.25% vs. 26.11%, P = 0.001 respectively), and pathogenic TSC1 inactivating mutations were enriched in local tumors (67.3% vs. 37.8%, P = 0.008). Median overall survival from BM diagnosis was 9 months (range 0-27). HNSCC patients with BM frequently have oropharyngeal primary sites and are HPV+. Common molecular alterations in BM samples, including targetable PIK3CA and ATM, were identified. MAP2K2 alterations were enriched and densities of immune cells were low, highlighting potential targets for further research and immunotherapy considerations.
Sections du résumé
BACKGROUND
BACKGROUND
Brain metastasis (BM) is a rare but severe complication of head and neck squamous cell carcinoma (HNSCC), with limited knowledge of molecular characteristics and immunogenicity.
METHODS
METHODS
We analyzed 61 cases of HNSCC-BM from three academic institutions (n = 24) and Foundation Medicine Inc (FMI, n = 37). A subset of cases underwent next-generation sequencing, multiple immunofluorescence, and proximity ligation sequencing. Gene enrichment analysis compared alterations in FMI BM samples (n = 37) with local samples (n = 4082).
RESULTS
RESULTS
Demographics included: median age of 59 years, 75% male, 55% current/former smokers, 75% oropharyngeal primary, and 67% human papillomavirus (HPV) +. ATM (54%), KMT2A (54%), PTEN (46%), RB1 (46%), and TP53 (46%) were frequently altered in BM samples from academic centers (62% HPV/p16+). Structural rearrangements ranged from 9 to 90 variants by proximity ligation sequencing. BMs had low densities of CD8+, PD-1+, PD-L1+, and FOXP3 + cells, and 92% had PD-L1 combined positive scores < 1%. CDKN2A (40.5%), TP53 (37.8%), and PIK3CA (27.0%) alterations were common in the FMI BMs (51% HPV+). MAP2K2 alterations and HPV + signature were enriched in FMI BMs compared to local tumors (11.8% vs. 6.4%, P = 0.005 and 51.25% vs. 26.11%, P = 0.001 respectively), and pathogenic TSC1 inactivating mutations were enriched in local tumors (67.3% vs. 37.8%, P = 0.008). Median overall survival from BM diagnosis was 9 months (range 0-27).
CONCLUSIONS
CONCLUSIONS
HNSCC patients with BM frequently have oropharyngeal primary sites and are HPV+. Common molecular alterations in BM samples, including targetable PIK3CA and ATM, were identified. MAP2K2 alterations were enriched and densities of immune cells were low, highlighting potential targets for further research and immunotherapy considerations.
Identifiants
pubmed: 39438862
doi: 10.1186/s12967-024-05761-z
pii: 10.1186/s12967-024-05761-z
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
960Informations de copyright
© 2024. The Author(s).
Références
Leeman JE, Li Jgao, Pei X, et al. Patterns of treatment failure and postrecurrence outcomes among patients with locally Advanced Head and Neck squamous cell Carcinoma after Chemoradiotherapy using Modern Radiation techniques. JAMA Oncol. 2017;3(11):1487. https://doi.org/10.1001/jamaoncol.2017.0973 .
doi: 10.1001/jamaoncol.2017.0973
pubmed: 28542679
pmcid: 5710194
Kotwall C, Sako K, Razack MS, Rao U, Bakamjian V, Shedd DP. Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg. 1987;154(4):439–42. https://doi.org/10.1016/0002-9610(89)90020-2 .
doi: 10.1016/0002-9610(89)90020-2
pubmed: 3661849
Liu AK, Wu J, Berthelet E, et al. Clinical features of head and neck cancer patients with brain metastases: a retrospective study of 88 cases. Oral Oncol. 2021;112:105086. https://doi.org/10.1016/j.oraloncology.2020.105086 .
doi: 10.1016/j.oraloncology.2020.105086
pubmed: 33186892
Zbaren P, Lehmann W. Frequency and sites of distant metastases in Head and Neck squamous cell carcinoma: an analysis of 101 cases at autopsy. Arch Otolaryngol - Head Neck Surg. 1987;113(7):762–4. https://doi.org/10.1001/archotol.1987.01860070076020 .
doi: 10.1001/archotol.1987.01860070076020
pubmed: 3580159
Li D, Li X, Zhao J, Tan F. Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma. J Transl Med. 2022;20(1):358. https://doi.org/10.1186/s12967-022-03559-5 .
doi: 10.1186/s12967-022-03559-5
pubmed: 35962347
pmcid: 9373390
Ghosh-Laskar S, Agarwal J, Yathiraj P, et al. Brain metastasis from nonnasopharyngeal head and neck squamous cell carcinoma: a case series and review of literature. J Cancer Res Ther. 2016;12(3):1160. https://doi.org/10.4103/0973-1482.184525 .
doi: 10.4103/0973-1482.184525
pubmed: 28054528
Bree RD, Mehta DM, Snow GB, Quak JJ. Intracranial metastases in patients with squamous cell carcinoma of the Head and Neck. Otolaryngol Neck Surg. 2001;124(2):217–21. https://doi.org/10.1067/mhn.2001.112478 .
doi: 10.1067/mhn.2001.112478
Ruzevick J, Olivi A, Westra WH. Metastatic squamous cell carcinoma to the brain: an unrecognized pattern of distant spread in patients with HPV-related head and neck cancer. J Neurooncol. 2013;112(3):449–54. https://doi.org/10.1007/s11060-013-1075-9 .
doi: 10.1007/s11060-013-1075-9
pubmed: 23408186
pmcid: 3630253
Huang SH, Perez-Ordonez B, Liu FF, et al. Atypical clinical behavior of p16-Confirmed HPV-Related Oropharyngeal squamous cell carcinoma treated with Radical Radiotherapy. Int J Radiat Oncol. 2012;82(1):276–83. https://doi.org/10.1016/j.ijrobp.2010.08.031 .
doi: 10.1016/j.ijrobp.2010.08.031
Bulut OC, Lindel K, Hauswald H, et al. Clinical and molecular characteristics of HNSCC patients with brain metastases: a retrospective study. Eur Arch Otorhinolaryngol. 2014;271(6):1715–22. https://doi.org/10.1007/s00405-013-2665-z .
doi: 10.1007/s00405-013-2665-z
pubmed: 23990032
The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–82. https://doi.org/10.1038/nature14129 .
doi: 10.1038/nature14129
Hanna GJ, Lizotte P, Cavanaugh M, et al. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018;3(4):e98811. https://doi.org/10.1172/jci.insight.98811 .
doi: 10.1172/jci.insight.98811
pubmed: 29467336
pmcid: 5916245
Nowak JA, Yurgelun MB, Bruce JL, et al. Detection of Mismatch Repair Deficiency and microsatellite instability in colorectal adenocarcinoma by targeted next-generation sequencing. J Mol Diagn JMD. 2017;19(1):84–91. https://doi.org/10.1016/j.jmoldx.2016.07.010 .
doi: 10.1016/j.jmoldx.2016.07.010
pubmed: 27863258
Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023–31. https://doi.org/10.1038/nbt.2696 .
doi: 10.1038/nbt.2696
pubmed: 24142049
pmcid: 5710001
Milbury CA, Creeden J, Yip WK, et al. Clinical and analytical validation of FoundationOne
doi: 10.1371/journal.pone.0264138
pubmed: 35294956
pmcid: 8926248
Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. https://doi.org/10.1186/s13073-017-0424-2 .
doi: 10.1186/s13073-017-0424-2
pubmed: 28420421
pmcid: 5395719
Trabucco SE, Gowen K, Maund SL, et al. A Novel Next-Generation sequencing Approach to detecting microsatellite instability and Pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples. J Mol Diagn JMD. 2019;21(6):1053–66. https://doi.org/10.1016/j.jmoldx.2019.06.011 .
doi: 10.1016/j.jmoldx.2019.06.011
pubmed: 31445211
Knepper TC, Montesion M, Russell JS, et al. The genomic Landscape of Merkel Cell Carcinoma and clinicogenomic biomarkers of response to Immune checkpoint inhibitor therapy. Clin Cancer Res off J Am Assoc Cancer Res. 2019;25(19):5961–71. https://doi.org/10.1158/1078-0432.CCR-18-4159 .
doi: 10.1158/1078-0432.CCR-18-4159
Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–28. https://doi.org/10.1016/S0140-6736(19)32591-7 .
doi: 10.1016/S0140-6736(19)32591-7
pubmed: 31679945
Haddad RI, Harrington K, Tahara M, et al. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line treatment for Recurrent/Metastatic squamous cell carcinoma of the Head and Neck: The Final results of CheckMate 651. J Clin Oncol. 2023;41(12):2166–80. https://doi.org/10.1200/JCO.22.00332 .
doi: 10.1200/JCO.22.00332
pubmed: 36473143
Narayan P, Prowell TM, Gao JJ, et al. FDA approval Summary: Alpelisib Plus Fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or metastatic breast Cancer. Clin Cancer Res. 2021;27(7):1842–9. https://doi.org/10.1158/1078-0432.CCR-20-3652 .
doi: 10.1158/1078-0432.CCR-20-3652
pubmed: 33168657
Cetuximab approved by FDA for treatment of head and neck squamous cell cancer. Cancer Biol Ther. 2006;5(4):340–342.
Fallah J, Xu J, Weinstock C, et al. FDA approval Summary: Olaparib in Combination with Abiraterone for treatment of patients with BRCA -Mutated metastatic castration-resistant prostate Cancer. J Clin Oncol. 2024;42(5):605–13. https://doi.org/10.1200/JCO.23.01868 .
doi: 10.1200/JCO.23.01868
pubmed: 38127780
Sacco AG, Chen R, Worden FP, et al. Pembrolizumab plus Cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021;22(6):883–92. https://doi.org/10.1016/S1470-2045(21)00136-4 .
doi: 10.1016/S1470-2045(21)00136-4
pubmed: 33989559
Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with Oropharyngeal Cancer. N Engl J Med. 2010;363(1):24–35. https://doi.org/10.1056/NEJMoa0912217 .
doi: 10.1056/NEJMoa0912217
pubmed: 20530316
pmcid: 2943767
Tommasino M. The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol. 2014;26:13–21. https://doi.org/10.1016/j.semcancer.2013.11.002 .
doi: 10.1016/j.semcancer.2013.11.002
pubmed: 24316445
Sabatini ME, Chiocca S. Human papillomavirus as a driver of head and neck cancers. Br J Cancer. 2020;122(3):306–14. https://doi.org/10.1038/s41416-019-0602-7 .
doi: 10.1038/s41416-019-0602-7
pubmed: 31708575
Martinelli E, Morgillo F, Troiani T, Ciardiello F. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: the role of MEK. Cancer Treat Rev. 2017;53:61–9. https://doi.org/10.1016/j.ctrv.2016.12.001 .
doi: 10.1016/j.ctrv.2016.12.001
pubmed: 28073102
Huang Q, Li F, Hu H, et al. Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non–small cell lung cancer. Sci Adv. 2022;8(5):eabi9533. https://doi.org/10.1126/sciadv.abi9533 .
doi: 10.1126/sciadv.abi9533
pubmed: 35119931
pmcid: 8816329
Zedan W, Mourad MI, El-Aziz SMA, Salamaa NM, Shalaby AA. Cytogenetic significance of chromosome 17 aberrations and P53 gene mutations as prognostic markers in oral squamous cell carcinoma. Diagn Pathol. 2015;10(1):2. https://doi.org/10.1186/s13000-015-0232-1 .
doi: 10.1186/s13000-015-0232-1
pubmed: 25881131
pmcid: 4340679
Di Sante G, Pagé J, Jiao X, et al. Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology. Expert Rev Anticancer Ther. 2019;19(7):569–87. https://doi.org/10.1080/14737140.2019.1615889 .
doi: 10.1080/14737140.2019.1615889
pubmed: 31219365
pmcid: 6834352
Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130–46. https://doi.org/10.1038/nrd4504 .
doi: 10.1038/nrd4504
pubmed: 25633797
pmcid: 4480421
Allen F, Maillard I. Therapeutic targeting of Notch Signaling: from Cancer to Inflammatory disorders. Front Cell Dev Biol. 2021;9:649205. https://doi.org/10.3389/fcell.2021.649205 .
doi: 10.3389/fcell.2021.649205
pubmed: 34124039
pmcid: 8194077
Nishikawa S, Iwakuma T. Drugs targeting p53 mutations with FDA approval and in clinical trials. Cancers. 2023;15(2):429. https://doi.org/10.3390/cancers15020429 .
doi: 10.3390/cancers15020429
pubmed: 36672377
pmcid: 9856662
Moroney MR, Woodruff E, Qamar L, et al. Inhibiting Wnt/beta-catenin in CTNNB1 ‐mutated endometrial cancer. Mol Carcinog. 2021;60(8):511–23. https://doi.org/10.1002/mc.23308 .
doi: 10.1002/mc.23308
pubmed: 34038589
Rosas D, Raez LE, Russo A, Rolfo C. Neuregulin 1 Gene (NRG1). A potentially new Targetable Alteration for the treatment of Lung Cancer. Cancers. 2021;13(20):5038. https://doi.org/10.3390/cancers13205038 .
doi: 10.3390/cancers13205038
pubmed: 34680187
pmcid: 8534274
McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet. 2021;398(10302):803–16. https://doi.org/10.1016/S0140-6736(21)00438-4 .
doi: 10.1016/S0140-6736(21)00438-4
pubmed: 34454676
Portnow J, Wang D, Blanchard MS, et al. Systemic Anti–PD-1 Immunotherapy results in PD-1 blockade on T cells in the Cerebrospinal Fluid. JAMA Oncol. 2020;6(12):1947. https://doi.org/10.1001/jamaoncol.2020.4508 .
doi: 10.1001/jamaoncol.2020.4508
pubmed: 33030521
Brastianos PK, Carter SL, Santagata S, et al. Genomic characterization of Brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015;5(11):1164–77. https://doi.org/10.1158/2159-8290.CD-15-0369 .
doi: 10.1158/2159-8290.CD-15-0369
pubmed: 26410082
pmcid: 4916970
Skakodub A, Walch H, Tringale KR, et al. Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis. Nat Commun. 2023;14(1):4980. https://doi.org/10.1038/s41467-023-40793-x .
doi: 10.1038/s41467-023-40793-x
pubmed: 37591896
pmcid: 10435547
Abboodi F, Buckhaults P, Altomare D, et al. HPV-inactive cell populations arise from HPV16-transformed human keratinocytes after p53 knockout. Virology. 2021;554:9–16. https://doi.org/10.1016/j.virol.2020.12.005 .
doi: 10.1016/j.virol.2020.12.005
pubmed: 33321328